Effect of Captopril on Plasma Prolactin in Patients with Essential Hypertension

Abstract

The effects of the angiotensin-converting enzyme inhibitor captopril on blood pressure, heart rate, plasma prolactin, and renin activity were examined in a single-blind, placebo-controlled trial on 30 patients with essential hypertension (15 given drug, 15 placebo). Captopril, 25 mg administered orally, reduced the blood pressure and increased the plasma renin activity. Captopril decreased mean plasma prolactin from 17.5±1.4 ng/mL to 9.1±1.0 ng/mL (p<0.001). Significant correlation was found between captopril-induced change from control values of plasma prolactin (Δplasma prolactin) vs Δplasma renin activity (r = -0.688, p<0.001). These results suggest that acute administration of captopril was accompanied by a reduction in plasma prolactin and that this reduction may be of clinical significance during therapy of hypertension.